Edgewise Therapeutics, Inc. — Director's Dealing 2021

Apr 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edgewise Therapeutics, Inc. (EWTX)
CIK: 0001710072
Period of Report: 2021-03-30

Reporting Person: ROOT JONATHAN D (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-30	Common Stock	C	3473543	$0.00	Acquired	3473543	Indirect
2021-03-30	Common Stock	P	15625	$16.00	Acquired	15625	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-30	Series B-1 Preferred Stock	$0.00	C	1651607	Disposed		Common Stock (1651607)	Indirect
2021-03-30	Series B-2 Preferred Stock	$0.00	C	1366707	Disposed		Common Stock (1366707)	Indirect
2021-03-30	Series C Preferred Stock	$0.00	C	455229	Disposed		Common Stock (455229)	Indirect

Footnotes

F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock converted into one share of the Issuer's Common Stock immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2: These securities are held of record by U.S. Venture Partners XI, L.P. ("USVP XI"). Presidio Management Group XI, L.L.C. ("PMG XI"), the general partner of USVP XI, has sole voting and dispositive power with respect to the shares held by USVP XI. The Reporting Person is a managing member of PMG XI with additional rights with respect to the issuer's securities, and may be deemed to have sole voting and dispositive power with respect to such shares. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.